A novel locus of resistance to severe malaria in a region of ancient balancing selection by Band, Gavin et al.
A novel locus of resistance to severe malaria in a region of 
ancient balancing selection
Malaria Genomic Epidemiology Network 1
The high prevalence of sickle haemoglobin in Africa shows that malaria has been a major 
force for human evolutionary selection, but surprisingly few other polymorphisms have been 
proven to confer resistance to malaria in large epidemiological studies1–3. To address this 
problem we conducted a multi-centre genome-wide association study (GWAS) of life-
threatening Plasmodium falciparum infection (severe malaria) in over 11,000 African 
children with replication data in a further 14,000 individuals. Here we report a novel malaria 
resistance locus close to a cluster of genes encoding glycophorins that are receptors for 
erythrocyte invasion by P. falciparum. We identify a haplotype at this locus which provides 
33% protection against severe malaria (OR=0.67, 95%CI=0.60–0.76, P=9.5×10−11) and is 
linked to polymorphisms previously shown to have features of ancient balancing selection, 
based on haplotype sharing between humans and chimpanzees4. Taken together with 
previous observations on the malaria-protective role of blood group O1–3,5, these data reveal 
that two of the strongest GWAS signals for severe malaria lie in or close to genes encoding 
the glycosylated surface coat of the erythrocyte cell membrane, both within regions of the 
genome where it appears that evolution has maintained diversity for millions of years. These 
findings provide new insights into the host-parasite interactions that are critical in 
determining the outcome of malaria infection.
In the discovery phase of this study we analysed GWAS data on 5,633 children with severe 
malaria and 5,919 population controls from The Gambia, Kenya and Malawi, and in the 
replication phase we analysed candidate SNPs in a further 13,946 case control samples from 
Burkina Faso, Cameroon, The Gambia, Ghana, Malawi, Mali and Tanzania (Extended Data 
Figure 1). The majority of samples used in the discovery phase have been analysed 
previously by lower resolution GWAS methods3. For this analysis we improved resolution 
by directly typing all samples at approximately 2.5 million SNPs using the Illumina 
Omni2.5M platform, followed by quality control (Extended Data Figures 1 and 2) and 
imputation of genotypes at over 10 million SNPs using haplotype data from the 1000 
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Genomes Project6. Imputation performance varied across populations, with accuracy 
decreasing as a function of the similarity between study and reference individuals (Extended 
Data Figure 3). When testing for genetic association, principal components analysis was 
used to correct for population structure (Extended Data Figure 4a–e) which reflected both 
geography and self-reported ethnicity. Similar results were obtained using a mixed-model 
approach (Extended Data Figure 4f).
To assess the evidence for association in the discovery phase we used an approach which 
allows for heterogeneity in the protective effect of an allele across different study sites. This 
could be particularly important in our data as high levels of genetic and ethnic diversity in 
Africa can result in variable patterns of linkage disequilibrium between study sites that can 
complicate GWAS analysis7. Other potential sources of heterogeneity include allelic 
heterogeneity and multiple independent origins of malaria resistance loci, as has been well 
documented at the HBB locus1,3, as well as the high levels of genetic diversity in the 
parasite8. Specifically, we used a Bayesian approach that combines evidence across multiple 
models of association by specifying a prior probability on the size and similarity of genetic 
effect across populations, as well as the mode of inheritance1. A single statistical summary 
of the signal of association was obtained by averaging the evidence across models, 
weighting each by its prior probability, and comparing the evidence to the null model of no 
association (model averaged Bayes factor; BFavg). Having observed the data, a posterior 
probability was assigned to each model (Prmodel) conditional on it being a true association 
and the model assumptions, which are described in the Methods and Extended Data Figure 
5. We replicated previously reported GWAS signals2,3,9 at the HBB (BFavg=5.8×1024), ABO 
(BFavg=6.7×109) and ATP2B4 (BFavg=4.4×105) loci, and a detailed analysis of key variants 
at these and other previously reported loci is presented elsewhere1. A previously reported 
association near the gene MARVELD32 did not replicate in this dataset (Supplementary Note 
1). Genome-wide patterns of association with severe malaria at the 34 regions of the genome 
containing a variant with either a Bayes factor for the most probable model (BFmax) > 
2.5×104 or with a model averaged Bayes factor (BFavg) > 2.5×103 are summarised in 
Extended Data Figure 6 and Supplementary Table 1. Details of the evidence for association 
in these regions can be viewed online at www.malariagen.net/resource/14.
These data provide a rich resource of new candidate loci for further investigation. Here we 
focus on a region of chromosome 4 shown in Figure 1, where the strongest signal of 
association (at SNP rs184895969) is located between the gene FREM3 and a cluster of three 
glycophorin genes (GYPE, GYPB and GYPA). Glycophorins are sialoglycoproteins that are 
abundantly expressed in the erythrocyte membrane, providing a hydrophilic surface coat that 
is necessary for erythrocytes to flow freely in the circulation. A complex system of single-
nucleotide and structural variants in this region determine the MNS blood group system10. 
These genes play a functional role in invasion of erythrocytes by P. falciparum. Glycophorin 
A is the receptor for the P. falciparum erythrocyte-binding ligand EBA-17511, and 
glycophorin B is a receptor for the parasite ligand EBL-112. To follow up this observation, 
selected SNPs at this locus were genotyped by Sequenom iPLEX MassArray in the 
discovery and replication sample sets outlined above (Figure 1 and Extended Data Figure 
7a). The combined dataset of 25,498 samples provided convincing evidence of association at 
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rs186873296 by standard fixed-effect meta-analysis (P = 9.5×10−11) as well as by the above 
Bayesian approach (BFoverall = 1.3×108; Figure 2 and Methods). The minor allele frequency 
of rs186873296 was higher in East Africa than West Africa, and the greatest evidence of 
association was seen in Kenya where it was most common, with an allele frequency of 
approximately 10%. Using only replication data to avoid winner’s curse, and assuming an 
additive model, we estimate that carrying one copy of the derived (non-ancestral) allele 
reduces the risk of severe malaria by about 40% in Kenya (OR = 0.60, 95% CI=0.46–0.79), 
with a slightly smaller effect across all populations (OR = 0.67, 95%CI 0.56–0.80 in 
frequentist fixed-effect meta-analysis). Further details are given in Supplementary Note 2.
The glycophorin gene cluster has a complex pattern of gene conversion and structural 
variation that has been previously noted; indeed it has been proposed that selective pressure 
due to pathogens, including malaria, has contributed to shaping diversity in this 
region10,13–16. Using the human reference sequence and mapped sequence read data from 
the 1000 Genomes Project, we identified the boundaries of a 350kb region of sequence 
homology surrounding these genes as well as a set of segregating gene deletions (Extended 
Data Figure 8). The lead imputed marker (rs184895969) is located within 10kb of this 
complex region. Imputation accuracy within the region is low using current reference data, 
so it is possible that the causal variant lies within the glycophorin genes themselves but that 
this is obscured in the current imputed dataset. With this caveat, we computed a credible set 
of putatively causal variants in the region; this set includes both the lead imputed marker and 
a linked missense mutation (rs181620317) in FREM3 (Extended Data Figure 7b). We note 
that the protective allele at rs184895969 was associated with increased GYPA transcription 
in published gene expression data for HapMap lymphoblastoid cell lines17 (P = 0.016; 
Extended Data Figure 9); other regional analyses are described in Supplementary Notes 1–2. 
Improved African genome variation reference panels7,18 are needed to understand the 
complex patterns of variation in this region so that the causal variant of malaria resistance 
can be fine-mapped with greater confidence.
A striking feature of these data is that all of the loci which reach conventional criteria for 
genome-wide significance (P < 5×10−8 using a fixed effects model) are in or near genes that 
play a key role in erythrocytes (HBB, ABO, ATP2B4, FREM3/GYPE), the primary host cell 
of P. falciparum. Other erythrocyte-related genes are identified in the discovery phase 
analysis but do not reach genome-wide significance, including EPB41, which encodes 
erythrocyte membrane protein band 4.1 and has been implicated as a possible receptor for P. 
falciparum invasion19 (rs2985337: BFavg=3443; fixed-effect meta-analysis OR=1.16, 
95%CI=1.09–1.23, P=1.2×10−6; see Extended Data Figure 6).
An intriguing feature of the ABO locus is that it contains a number of polymorphisms that 
are shared between humans and other primates, and recent analyses of sequence variation 
across species indicated that some of these are ancient polymorphisms that have been 
maintained by balancing selection over millions of years20. The current findings are of 
particular interest since the FREM3/GYPE is one of the most prominent examples of 
putative ancient balancing selection in a genome-wide analysis of haplotype sharing 
between humans and chimpanzees4. The peak GWAS signal at this locus is less than 45kb 
away from the shared human-chimp haplotype, which falls within the region covered by the 
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credible set (Extended Data Figure 7b), although it does not exhibit a strong association with 
severe malaria (Supplementary Note 3). To explore the genealogical relationship between 
the putative ancient balanced polymorphisms (ABPs) and SNPs associated with severe 
malaria in the FREM3/GYPE region, we inferred an ancestral tree21 from the African (YRI 
+ LWK) part of the 1000 Genomes data and used it to order haplotypes in the region, 
labelled with the positions of ABPs, malaria-associated SNPs, and other variants of interest 
(Figure 3). All three haplotypes carrying the protective allele at the directly-typed marker 
with most evidence of association (rs186873296) carry the minor allele at the ABP markers 
(D’=1, P=0.017). By inferring the positions of putative causal mutations on the estimated 
genealogical tree21 at the lead imputed marker (rs184895969) we found evidence for a 
single protective mutation in Kenya (log10 BF=3.09; OR=0.6) estimated to lie on the branch 
ancestral to the protective allele at the lead marker. Although the most likely position for an 
additional mutation was on the branch ancestral to the ABPs, a single haplotype explains 
most of the signal of association in this region.
These observations raise the question of whether malaria resistance loci are more likely to 
be found in regions of the genome that show evidence of ancient balancing selection. We 
therefore analysed the relationship between the regions of association in our GWAS and 125 
regions of the genome found by Leffler et al4 to contain haplotypes shared between humans 
and chimpanzees. The SNPs defining these haplotypes (ABPs) were not themselves 
enriched for association with severe malaria (P > 0.1, Methods). We used a simulation 
approach to assess the physical proximity of ABPs to the peak of association within the 34 
strongest regions of association (tier 1) and 73 weaker signals (tier 2), and observed a 
significant relationship with tier 1 over a range of length scales (Extended Data Figure 
10a,d). We also identified the nearest gene to the lead marker within each association region 
as well as the gene nearest to each ABP haplotype, and performed a gene-based test for 
genome-wide enrichment. Strong evidence for enrichment was seen at tier 1 loci (OR 41.0; 
P=4×10−7 by Fisher’s exact test, Psim=5×10−4 using a simulation approach described in 
Methods, and P=1×10−4 using the INRICH algorithm22; Extended Data Figures 10b–d) and 
a weaker trend at tier 2 loci (OR 7.7, Psim=0.15). Apart from ABO and FREM3/GYPE, there 
were six other GWAS loci (4 in tier 1, 2 in tier 2) where the nearest gene to the lead marker 
was also the nearest gene to an ABP haplotype (DSCAM, NRG1, CNTNAP5, TMEM132C, 
CACNA2D1, RYR2). Although the current association evidence at these loci do not satisfy 
conventional criteria for genome-wide significance and they should be regarded as putative 
until convincingly replicated, it is noteworthy that they are all involved in key aspects of 
membrane biology (Supplementary Note 3).
In the largest genetic association study of malaria to date, we have identified a new locus of 
resistance to severe malaria that lies next to a cluster of glycophorin genes involved in 
erythrocyte invasion by P. falciparum, and that also overlaps a locus of putative ancient 
balancing selection identified by analysis of haplotype sharing between humans and 
chimpanzees. It is possible that malaria is not the cause of the ancient balancing selection, or 
that it is just one of a number of opposing evolutionary driving forces, as at ABO, where 
blood group O reduces the risk of severe malaria but increases the risk of severe cholera23. 
Nonetheless, these new findings raise the intriguing question of whether natural selection on 
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malaria susceptibility has been shaping genetic diversity in humans and their ancestors for 
millions of years. P. falciparum is closely related to the chimpanzee parasite P. reichenowi 
and other parasites of African Great Apes24–26. It has been proposed that P. falciparum was 
introduced into human populations from chimpanzees or gorillas in the recent past, but this 
remains a matter of intense debate25–27. Population genetic data are consistent with an 
ancient origin followed by a marked expansion of the parasite population approximately ten 
thousand years ago, coincident with the introduction of agriculture28. The P. falciparum 
genome possesses a huge repertoire of polymorphism8 and it is possible that the host and 
parasite genomes are engaged in a longstanding evolutionary arms race, each maintaining 
diversity to try to outflank the other29. Intriguingly, the parasite surface receptor EBA-175, 
which directly binds glycophorin A during red cell invasion, also contains structural 
polymorphisms with features of ancient dimorphism30. The present findings provide new 
leads both to investigate these evolutionary mechanisms and to discover further genetic 
determinants of resistance to severe malaria in African children.
Methods
Samples, ethics and clinical information
Samples were collected from nine partner projects from across sub-Saharan Africa 
(Extended Data Figure 1a) as described previously1,3. The studies and sample sets described 
in this manuscript form part of a larger ongoing project within the Malaria Genomic 
Epidemiology Network (www.malariagen.net). We used the World Health Organisation 
definition of severe malaria which comprises a broad spectrum of life-threatening clinical 
complications of Plasmodium falciparum infection29,31. Investigators from study sites 
worked together to agree on principles for sharing data and standardising clinical definitions, 
and to define best ethical practices across different local settings including the development 
of guidelines for informed consent. Relevant ethics committees are listed in Extended Data 
Figure 1a. Further information on policies, research and the consent process may be found 
on the MalariaGEN website (http://www.malariagen.net/community/ethics-governance).
DNA extraction and Sequenom typing
As described previously1,3, all samples submitted to the MalariaGEN Resource Centre 
underwent a standard set of procedures that included quantification using picogreen, 
genotyping of 65 polymorphisms (including HbS - rs334, and 3 gender-typing SNPs) on the 
Sequenom iPLEX MassArray platform and matching to baseline clinical data (e.g. gender, 
ethnic group and case-control status).
High-density genotyping
Three cohorts (Gambia, Malawi and Kenya) were genotyped on the Illumina 
HumanOmni2.5–4 (Kenya) and Illumina HumanOmni2.5–8 (Gambia, Malawi) platforms. 
As described previously3 we used three different calling algorithms (Illuminus32, Illumina’s 
Gencall algorithm as provided in BeadStudio, and GenoSNP33), each of which uses slightly 
different information in the data. We formed final genotype calls by taking consensus 
between the three algorithms. Genotypes where any two of the three calling algorithms were 
discordant, and genotypes where fewer than two algorithms were confident enough to make 
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a call were treated as missing. This process showed improved calling, evaluated using 
Mendelian error counts in a subset of Kenyan samples, relative to each of the three 
algorithms separately (data not shown).
Following genotype calling, we aligned genotypes to the forward strand of the human 
reference sequence (GRCh37), using both the Illumina-supplied manifest and publically 
available strand files (www.well.ox.ac.uk/~wrayner/strand) obtained by mapping allele 
probes to the reference by BLAT34. We removed SNPs whose position or strand 
mismatched between the Illumina manifest and the strand file. To simplify analyses, we 
restricted attention to the set of SNPs having the same name, chromosome, position, strand, 
and probe sequences across the two genotyping platforms. Because the Omni2.5M contains 
multiple probes for some variants, we further removed SNPs to ensure positions were 
unique. In total we were left with 2322985 SNPs in each cohort across the autosomes and 
the X and Y chromosomes. We note that SNPs annotated as lying on the pseudo-autosomal 
region (PAR) of the X chromosome were not included, as these had position equal to 0 in 
the manifest for the HumanOmni2.5–4 array. Finally, we flipped alleles where necessary so 
that in downstream analyses the first allele always corresponds to the reference allele of the 
human genome sequence.
Sample Quality Control
We performed sample QC separately on each cohort by computing autosome-wide averages 
of normalised X channel intensity, normalised Y channel intensity, and heterozygosity and 
missingness based on the consensus call. To identify outlying samples we applied 
ABERRANT35, adjusting the lambda parameter per cohort to account for differences in 
genotyping quality (Extended Data Figure 1d–f). In Gambia, a tail of samples showing low 
heterozygosity but otherwise appearing to be well typed was apparent. We explicitly 
included these samples in downstream analyses.
To estimate genome-wide relatedness between samples, we selected a list of 178775 high 
quality SNPs satisfying the criteria missingness < 1%, MAF > 1% and thinned to be at least 
0.005cM apart and to have pairwise r2 < 0.3. Treating each cohort separately, we used 
SHELLFISH (www.stats.ox.ac.uk/~davison/software/shellfish/shellfish.php) to compute a 
matrix of pairwise relatedness values R = (rij) between samples, where rij denotes the 
genome-wide average covariance of frequency-normalised genotypes in individuals i and j. 
In samples with few close relationships, the value of rij can be thought of as an estimate of 
kinship36 with, for example, values close to 1 representing identity between samples, and 
values close to zero reflecting a lack of close relatedness (relative to the rest of the sample). 
To remove samples with duplicate typing and close relationships, we excluded one of each 
pair of samples with rij > 0.2, taking all remaining samples through to phasing and 
imputation. Extended Data Figure 1c lists the number of samples before and after QC, and 
the number removed by each QC step; (*) denotes the number of samples removed after 
explicitly including samples with low heterozygosity in Gambia.
We used SHELLFISH to compute principal components (PCs) on the post-QC sample set. 
Consistent with our removal of poor quality, duplicate and closely related samples, principal 
components plots show no substantially outlying samples (see Extended Data Figure 4a–c). 
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The top few principal components in each cohort reflect substantial population structure, as 
evidenced by colouring by reported ethnicity. As found previously3,9, the top principal 
components are also significantly correlated with case-control status (Extended Data Figure 
4d), indicating that population structure may act as a confounding factor in association 
analyses if not controlled.
Genotyping Quality Control
Treating each cohort separately, we used SNPTEST (mathgen.stats.ox.ac.uk/
genetics_software/snptest/snptest.html) to test for association at each autosomal SNP using a 
genotypic model of association which allows for different effects at heterozygote and 
homozygote genotypes, including the leading 5 principal components as covariates. 
Genotypic model association tests are particularly sensitive to confounding by genotyping 
error37, and we used the resulting P-values as a guide to finding appropriate QC criteria. To 
detect potential spurious genotypes due to batch effects, we modelled genotypes as predicted 
by the leading 5 principal components and case/control status in a linear regression 
framework in R38, and tested whether including an indicator of the plate on which each 
sample was genotyped contributed significantly to model fit. We refer to this as the “Plate 
test”. For downstream analyses we excluded SNPs with minor allele frequency < 1%, 
missing data proportion > 5% (in Gambia and Malawi) or > 2.5% (in Kenya, which had 
fewer missing genotypes overall), Hardy-Weinberg P < 1×10−20 in controls, or Plate-test P 
< 0.01. We inspected cluster plots of all remaining SNPs showing association test P < 
1×10−5 (Gambia) or P < 1×10−4 (Kenya, Malawi) and excluded those with clear genotyping 
problems. Extended Data Figure 2a shows the number of SNPs excluded by each criterion. 
The post-exclusion genome-wide association analysis is shown in Extended Data Figure 2c.
SNP QC on the X chromosome was performed as on the autosomes, with a few differences 
as follows. We treated males and females separately, using a genotypic model of association 
in females and an allelic model in males (who have only one copy of the X chromosome). 
Because genotype calling was performed blind to the gender of samples, some males appear 
to be heterozygous at some X chromosome SNPs. We treated all such heterozygous calls as 
missing. We computed missing data proportion and plate test P-values in males and females 
separately, and tested for departure from Hardy-Weinberg in female controls and for 
differences in frequency between males and females. We excluded SNPs with MAF < 1%, 
missingness > 5% (Gambia, Malawi) or 2.5% (Kenya) in males or females, or plate test P < 
0.01 in males or females. We further excluded SNPs with Hardy-Weinberg P < 1×10−20 in 
female controls or showing significant difference in allele frequencies between males and 
females (P < 1×10−20). Extended Data Figure 2b shows the number of SNPs excluded by 
each criterion.
Some regions of the X chromosome showed an elevated number of male heterozygote calls, 
contributing to the high number of SNPs excluded due to missingness in males. These 
included SNPs in the pseudo-autosomal regions at either end of the chromosome39 
(indicating that XY designation in the chip manifests does not adequately cover these 
regions) as well as SNPs within the X transposed region near the centromere.
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Phasing and imputation
We phased genotype data in each cohort separately using SHAPEIT v2.r64440, specifying 
200 hidden states and an effective population size of 17469, as recommended for African 
populations by the SHAPEIT documentation, and phasing each chromosome separately. We 
used IMPUTE v2.3.041,42 to impute phased genotypes into the 1000 Genomes6 Phase I 
integrated variant set (version of 24th August 2012, as downloaded from the IMPUTE 
website, which we refer to here as the 1000 Genomes reference panel) in 5Mb chunks with a 
buffer region of 500kb. For phasing and imputation we used the combined HapMap 
recombination map in build 37 coordinates included with the 1000 Genomes reference 
panel. Unless otherwise stated, downstream analyses included only SNPs with minor allele 
frequency > 0.5% and impute info metric > 0.75.
Assessment of imputation
At each genotyped SNP, IMPUTE computes squared correlation (referred to here as 
accuracy) and concordance between typed genotypes and genotypes obtained by masking 
the SNP and re-imputing. To assess imputation performance, we plotted the cumulative 
distribution of concordance (Extended Data Figure 3a) and accuracy (Extended Data Figure 
3b), accuracy by frequency (Extended Data Figure 3d) as well as average per-sample 
accuracy (Extended Data Figure 3c). We also assessed accuracy relative to direct typing on 
the Sequenom platform at variants typed in the FREM3/GYPE, ARL14 and INPP4B regions 
of association as described below.
Association testing and meta-analysis
Association testing—We used SNPTEST to test for association at approximately 38 
million variants obtained through imputation, including 5 PCs as covariates to control for 
population structure separately in each cohort. SNPTEST uses a missing data likelihood to 
account for the uncertainty in genotypes at imputed SNPs. We fit additive, dominant, 
recessive, and heterozygote models of association and ran SNPTEST separately in each 
imputation chunk. Below, we refer to the estimated effect size for population i and mode of 
inheritance m as βi,m and its estimated standard error as SEi,m.
Frequentist meta-analysis—For each SNP and each mode of inheritance (additive, 
dominant, recessive, heterozygote) we computed the fixed-effect inverse variance-weighted 
meta-analysis effect size, standard error, and P-value. In this context, fixed-effect meta-
analysis assumes a single true effect size which is identical between the three cohorts, and 
can be thought of as finding the maximum likelihood estimate of the effect size under the 
assumption that the likelihood in cohort i is proportional to the density of the normal 
distribution with mean βi,m and standard error SEi,m.
Bayesian meta-analysis—We have previously1,3 used Bayesian meta-analysis 
techniques to allow for between-population heterogeneity of effect sizes in these three 
cohorts. Here, we applied this method to compute Bayes factors for association under four 
modes of inheritance and six different models of correlation between cohorts. In this 
framework, true effect sizes are modelled by a multivariate normal distribution centred on 
zero and with a given prior covariance matrix which can be written as σ2P, where σ2 is a 
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prior variance controlling the magnitude of plausible effects and P is a prior correlation 
matrix.
The correlation models we used were:
Fixed effects (all elements of P equal to 1): as with frequentist fixed-effect meta-analysis, 
this assumes effect sizes are equal across the three cohorts.
Correlated effects (all off-diagonal elements of P equal to 0.96): this assumes effect sizes 
are similar but allows for some variability.
Independent effects (all off-diagonal elements of P equal to 0.1): this assumes there is little 
similarity between effect sizes in different cohorts.
Structured effects We also considered models where effects in the two East African 
populations (Kenya and Malawi) were more similar to each other than to that in Gambia. 
We assumed either effects were fixed between Kenya and Malawi and correlated (ρ=0.96) 
between East Africa and Gambia (we refer to this as the fixed-structured-effect model), or 
that effects were correlated (ρ=0.96) between Kenya and Malawi and largely independent 
with Gambia (ρ=0.1) (referred to as the correlated-structured-effect model).
We used prior variance parameters of σ2=0.22, reflecting a belief in relatively small effects 
(odds ratio < 1.5 with 95% probability)37, and σ2=0.752, reflecting a belief in larger effects 
(odds ratio < 4.5 with 95% probability).
To form a single summary measure of evidence for association we formed a model-averaged 
Bayes factor (BF), referred to as the mean BF and denoted BFavg, as a weighted average of 
model-specific Bayes factors using the following weighting scheme. We assigned weights of 
0.4 for additive mode of inheritance and 0.2 for dominant, recessive, or heterozygote modes 
of inheritance, reflecting a belief that variants which tag causal variants by LD are more 
likely to display additive effects. We assigned a weight of 0.4, 0.2, and 0.1 to fixed-, 
correlated-, and independent-effect models, and 0.2 and 0.1 to fixed-structured and 
correlated-structured effects models. Finally we assigned weight of 0.5 to small-effect 
models (σ2=0.22) and large-effect models (σ2=0.752). Overall prior weights were assigned 
by multiplying across these categories; for example, the model representing small effect size 
distribution, fixed-effect across cohorts with additive mode of inheritance (denoted small-
fix-add) was assigned prior weight equal to 0.5×0.4×0.4=0.08, while the model representing 
small, correlated-structured, dominant effects (denoted small-cor-str-dom) was assigned a 
prior weight of 0.5×0.1×0.2=0.01. For each SNP we also recorded the model having the 
highest posterior weight, and refer to its Bayes factor as the max BF (denoted BFmax). 
Extended Data Figure 5a depicts slices through the combined prior on effect sizes across 
three cohorts for additive effect models. The mean BF behaves similarly to a minimum over 
all four fixed-effect meta-analysis P-values, but additionally captures effects that vary 
between cohorts (Extended Data Figure 5b).
As described previously1,3, to computed model-specific Bayes factors efficiently we used an 
approximation of the likelihood by the density of a normal distribution with the estimated 
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mean (βi,m) and standard error (SEi,m) in each cohort. Thus, overall, observed effect sizes are 
modelled as normally distributed around zero with covariance that depends on the prior 
covariance in true effect sizes and on model standard errors,
where V is a diagonal matrix with ith diagonal entry equal to the squared standard error, 
SE2i,m. The approximate or asymptotic Bayes factor can then be computed by evaluating a 
ratio of two normal densities. In the univariate case this method is the same as described 
previously by Wakefield43. To facilitate working with genome-wide meta-analysis results, 
we wrote custom software to compute frequentist and Bayesian meta-analyses, and stored 
details of genotype counts, association model fit, and meta-analysis results directly in a 
SQLite database file.
Further discussion of the Bayesian approach can be found in Supplementary Note 4.
X chromosome association testing and meta-analysis
Association testing on the X chromosome was performed as for the autosomes with a few 
differences as follows. We ran SNPTEST separately in males and females, estimating effect 
sizes under additive, dominant, recessive and heterozygote modes of inheritance in females. 
In this usage, SNPTEST assumes a model of complete inactivation so encodes male 
genotypes as 0/1 and females as 0/0.5/1 for an additive mode of inheritance. We than meta-
analysed the six gender-specific association analyses to produce frequentist fixed-effect and 
model-averaged bayesian meta-analyses.
For Bayesian analysis, in addition to summing over models of between-population 
heterogeneity, we adopted the view that differences in sex might lead to heterogeneity in 
effect. We therefore included models of heterogeneity between males and females as 
follows. Let ρsex denote the correlation between effects in male and female samples within a 
single population. We included models where males and females have the same effect 
(ρsex=1, termed fixed-sex model and given prior weight 0.45), correlated effects (ρsex=0.96, 
termed correlated-sex model and given prior weight 0.225) or essentially independent 
effects (ρsex=0.1, termed independent-sex model and given prior weight 0.225). Because 
some parts of the X chromosome escape inactivation39,44, we also included a model where 
the effect in females is twice that in males (given prior weight 0.1).
To fully specify prior correlation for each model, for each pair of populations A,B we also 
need to specify the correlation (denoted ρcross) between males in A and females in B. We set 
ρcross = ρpop × ρsex where ρpop is the chosen prior correlation between same-sex samples in 
A and B (i.e. ρpop =1, 0.96 or 0.1 as defined above).
As above, we formed overall weights by multiplying across categories, so that for example 
the model of small, additive effects that are fixed across populations and across sexes 
(denoted small-fixsex-fix-add) had prior weight 0.5×0.4×0.4×0.45=0.036.
Page 10
Nature. Author manuscript; available in PMC 2016 April 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Linear mixed model analysis
To compare association test results for logistic regression as implemented in SNPTEST with 
the use of a linear mixed model, we reran association test scans in each discovery cohort 
using the program MMM45. We used the same genome-wide relatedness matrix as used to 
compute principal components (see above) and assumed an additive model of association. 
We plotted the –log10( P-value ) for MMM against the corresponding –log10( P-value ) 
based on the SNPTEST scan (which used 5 PCs as described above), for each discovery 
population and for fixed-effect meta-analysis (Extended Data Figure 4f). P-values under 
both methods at tier 1 loci are listed in Supplementary Table 1.
Lead SNPs, region and tier definitions
We formed a list of lead SNPs within approximately independent regions of interest as 
follows. We restricted to variants with IMPUTE info measure at least 0.75 across all three 
populations and ranked variants by the model-averaged Bayes factor (highest to lowest). We 
iteratively picked lead SNPs from the top of the list and excluded other variants within a 
recombination interval of 0.25cM±25kb centred at the lead SNP (referred to below as the 
association region), continuing until no more SNPs remained with BFavg>250 or 
BFmax>2500.
We grouped lead SNPs into two tiers as follows:
• tier 1: all lead SNPs with BFavg>2500 or BFmax>25000
• tier 2: all lead SNPs not in tier 1 with BFavg>1000 or BFmax>10000
In total, across the autosomes and the X chromosome there were 34 regions in tier 1 and 73 
in tier 2, with association regions covering approximately 13Mb and 26Mb of the genome 
respectively.
Regional association analysis
For each tier 1 and 2 region, we examined the pattern of association in the region, generating 
a regional association plot for the region annotated with details of the meta-analysis for the 
lead SNP as follows.
LD computation—In each region we computed pairwise LD statistics between the lead 
SNP and surrounding SNPs using best-guess imputed haplotypes for control samples across 
three populations. To facilitate this computation, we stored imputed haplotypes in a SQLite-
format database allowing us effective random access to haplotype data. We used R to 
compute both Pearson correlation coefficient (r2) and Lewontin’s |D’| between the lead SNP 
and all other SNPs in the region.
Regional association plot—For each SNP in tier 1 and 2 we plotted log10(BFavg) in the 
association region around the lead SNP plus 1Mb on either side, colouring points according 
to LD, with outer circles representing r2 and inner circles representing |D’|. We further 
annotated SNPs that were typed in at least one cohort (using black plusses) and SNPs that 
had Sequenom genotype data available (with black triangles).
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Regional annotations—We plotted all ABP variants (Supplementary Tables 4 and 5 of 
Leffler et al4), eQTLs from the Genotype-Tissue Expression project46 (GTEx), and 
previously reported47 GWAS loci. Where SNPs matched an imputed or typed variant, we 
computed LD statistics and coloured these points as above. We plotted all RefSeq genes (as 
downloaded from the UCSC Genome Browser MySQL database48 on 2013-03-18) in the 
region, annotating the direction of transcription. We further plotted local recombination rate 
estimates from the HapMap combined recombination map included with the IMPUTE 
haplotypes described above.
Meta-analysis—We annotated plots with effect sizes and confidence intervals for the lead 
SNP for each mode of inheritance (additive, dominant, recessive and heterozygote) that 
informed the model averaging. We also produced barplots showing the posterior distribution 
on models of association using the prior weights described above.
Cluster plots—Finally, for each region, we produced and inspected cluster plots for all 
typed SNPs with BFavg >= 10 that were not excluded by QC. As phasing fills in missing 
genotypes and potentially improves genotype calling based on LD with surrounding SNPs, 
we coloured plots based on genotype calls taken from the output of phasing.
Website—Regional association plots and cluster plots can be viewed online at http://
www.malariagen.net/resource/14.
Validation and replication typing
Based on a preliminary version of the data presented here we selected SNPs for typing on 
the Sequenom platform across the whole MalariaGEN Consortial Project 1 sample set, 
which includes the discovery samples, further cases and controls in the same populations 
that were not included in the GWAS, and further large sample sets from five other 
populations from sub-Saharan Africa (see Extended Data Figure 1a). Data were available for 
SNPs tagging the lead markers in the FREM3/GYPE, INPP4B and ARL14 regions (r2>0.5 in 
controls, as estimated using the EM algorithm) as well as other regions not represented in 
tier 1.
Replication analysis
Replication analysis using Sequenom data was restricted to the set of samples with less than 
10% missingness as measured across the set of 70 SNPs chosen for replication typing. In 
each population we conducted logistic regression in R, including five principal components 
(discovery samples) or reported ethnicity (replication samples) as covariates to control for 
population structure. For each GWAS lead SNP, we examined each Sequenom SNP in the 
region and computed r2 and |D’| with the lead SNP. To allow for the effects of incomplete 
LD on the Bayesian model fitting, we recomputed the Bayesian analysis in the discovery 
samples based on Sequenom genotypes at each SNP, to obtain a Sequenom-based mean 
Bayes factor and a ‘best model’ Bayes factor at the model with highest posterior weight. 
Where LD is incomplete or where imputation is imperfect, this model may differ from the 
best model for imputed data.
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For each SNP we computed fixed-effect meta-analysis across discovery samples, across 
replication samples, and across all samples. We also computed the Bayes factor for 
replication samples (BFreplication) for the model with highest posterior weight in the 
discovery samples. To compute an overall Bayes factor for association, we combined the 
discovery BFavg computed at the imputed lead marker with the replication bayes factor at 
the Sequenom SNP, as BFoverall = BFavg x BFreplication. We use the imputed lead marker 
here because the number of discovery samples directly typed was smaller than the number 
of imputed samples. Conditional on the lead imputed and replication markers reflecting the 
same signal of association, this BFoverall represents an overall measure of the evidence for 
association at the locus that reflects all the samples in our study.
A discussion of the replication evidence in the FREM3/GYPE, INPP4B and ARL14 regions 
can be found in Supplementary Note 1.
MalariaGEN encourages individual study sites to perform more detailed analyses of local 
patterns of disease association, and a Tanzanian-focused analysis of FREM3 and other 
candidate SNPs that were genotyped as part of this study is reported elsewhere49.
Credible interval analysis
In a given region of the genome, under the assumption that exactly one variant (that is 
accessible to our typing or imputation) is causal, the posterior probability that each variant is 
the causal variant can be computed by a simple reweighting of Bayes factors50. Using this 
approach we computed 95% and 99% credible intervals (i.e. the smallest set of SNPs 
accounting for 95% or 99% of the posterior mass) for variants in the association region 
around rs184895969, plus a margin of 50kb at either end (Extended Data Figure 7b). We 
noted that rs181620317, which is annotated as a missense mutation for the gene FREM3, is 
within the 95% confidence interval in our data. We note that while this analysis is simple 
and appealing, its interpretation depends on assumptions about the true disease model, and 
on the behaviour of imputation in the region50; in particular the difficulty of imputing 
variants around the three glycophorin genes (Extended Data Figure 8) might make this 
analysis fail to capture putatively important variation within or around GYPA, GYPB, or 
GYPE.
Sequence homology and alignability in the glycophorin region
To investigate the location of our GWAS signal with respect to the pattern of sequence 
homology around the three glycophorin genes, we generated a dot plot (Extended Data 
Figure 8a) showing co-occurrence of k-mers in the human reference sequence51 in the 
region. Considerable sequence homology was observed over a region of about 350kb 
covering the three genes. Our lead GWAS marker and the ABPs lie just outside this region.
The high level of homology should affect our ability to align probes or sequences to this part 
of the genome. To confirm this, we also plotted the UCSC alignability track (‘CRG 
alignability 100’, Extended Data Figure 8c), which shows the degree to which the 100-mer 
starting at each position in the reference sequence is alignable (with a value of 1/n indicating 
that the 100-mer aligns to n positions across the genome, allowing up to two mismatches). 
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As expected, even short regions of shared kmers affect alignability considerably, with 
alignability dropping to an average of about 0.7 within the large region of homology. 
Similarly, we plotted imputation performance (as measured by the IMPUTE info score) and 
observed a marked drop within the region of sequence homology.
Structural variation in the glycophorin region
We attempted to identify structural variation in the glycophorin region by examining 
sequence read data generated by the 1000 Genomes’ project, using the set of BAM files 
available from the 1000G project in October 2014, downloaded from ftp://ftp.
1000genomes.ebi.ac.uk/vol1/ftp/data. These data contain a mixture of read lengths, with 
most reads of at least 90bp and some reads of 76bp. We considered only reads with mappinq 
quality at least 20. For each sample we computed coverage across the glycophorin region, 
normalised by average coverage computed across chromosome 1, and refer to these values 
here as ‘coverage’.
Coverage values across the region were correlated with genome alignability (as defined 
above), with coverage dropping substantially in regions of low alignability. We therefore 
restricted attention to the set of perfectly alignable positions, here defined as positions such 
that every 100-mer overlapping the position in the reference sequence aligns uniquely, 
allowing up to two mismatches (and computed using the CRG alignability 100 track 
described above). As expected, coverage at perfectly alignable positions showed little or 
none of the variation present in genome alignability (Extended Data Figure 8e–g).
Two large structural variants, present at frequencies of at least 1% in LWK+YRI, were 
evident in coverage data. Genotypes for both these variants were called by the 1000 
Genomes phase I and are referred to as esv2668125 (also called MERGED_DEL_2_26708) 
and esv2662558 (also called MERGED_DEL_2_26722). Both deletions putatively represent 
deletions of all or part of GYPB. We noted some uncertainty as to the location of the 
breakpoints of both deletions - with 1000 Genomes’ breakpoints differing from the 
breakpoints as they appeared in coverage data by at least 10kb. We further noted that three 
samples (NA18519, NA19185, NA19222) that were called as heterozygote for one or both 
deletions by the 1000 Genomes project, appeared to have homozygous genotypes (red, blue 
and green lines, Extended Data Figure 8e–g).
Expression QTL analysis
To investigate the effect of associated SNPs in the FREM3 region on expression of nearby 
genes, we downloaded publically available data on RNA expression levels17 in HapMap 
samples, and plotted expression levels of genes in the region (Figure 1) against genotypes at 
the lead SNP and other SNPs of interest in African samples (YRI+LWK, Extended Data 
Figure 9). Data was available for genes INPP4B, USP38, GAB1, SMARCA5, GYPE, GYPB, 
GYPA, HHIP, ANAPC10 and ABCE1, with three probes available for GYPE, two for GAB1 
and one probe for each of the other genes. Five samples in this dataset (NA19318, 
NA19324, NA19377, NA19429, NA19190) carry the protective allele at the lead marker 
rs184895969, while only two carry the protective allele at the directly-typed rs186873296. 
For each gene and SNP we tested for a trend of genotype on expression using linear 
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regression. Extended Data 9 shows all probes for the glycophorins as well as other regional 
genes for which a P-value less than 0.05 was observed.
GENECLUSTER analysis
We used the program TREESIM21 to estimate an ancestral recombination graph for the 
LWK and YRI individuals in the 1000 Genomes Project haplotype data in a region from 
144.6Mb to 144.8Mb on chromosome 4 centred on the lead SNP in the FREM3 / GYPE 
region. We then ran GENECLUSTER21 in the region, allowing it to assign either one or two 
causal mutations in each marginal genealogy. GENECLUSTER works by probabilistically 
assigning study individuals to the tips of the tree estimated by TREESIM, and attempts to 
explain case/control status by assigning causal mutations to the branches of the tree in a 
Bayesian framework. This analysis is somewhat similar in spirit to our marginal SNP 
analysis, but has important differences. In particular, GENECLUSTER may detect 
associated mutations anywhere on the tree (which may not correspond directly to any typed 
or imputed variant), and can assess models of association involving more than a single 
causal variant. However, GENECLUSTER does not take into account principal components 
or otherwise control for population structure, and for computational reasons we only 
included the Luhyan (LWK) and Yoruban (YRI) populations from the 1000 Genomes 
reference panel in the analysis.
To investigate the relationship between ancestry and variants of interest, we plotted 
IMPUTE reference panel haplotypes in the region ordered by the marginal tree at the 
position of the imputed lead marker (rs184895969), annotating the lead imputed and 
Sequenom-typed markers, ABPs, previously reported GYPE eQTLs52, common deletions, 
and variants determining the M/N and S/s blood groups as described in Supplementary Note 
2 (Figure 3).
Analysis of enrichment of malaria-associated loci in functional categories
Full details of enrichment analyses are provided in Supplementary Note 3.
Code availability
The SNPTEST software for genome-wide association testing is available at https://
mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html.
Executables and source code for inthinnerator are available at http://www.well.ox.ac.uk/
~gav/inthinnerator.
Further software for generating key results for this paper will be made available at http://
www.malariagen.net/resource/14.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Extended Data
Extended Data Figure 1. 
Sample collections included in the study. a) Study sites and ethics approving institutions. b) 
Phenotypic makeup of discovery and replication samples from each site. 
‘UNCOMPLICATED’ refers to case individuals who were not identified as cerebral malaria 
(CM) or severe malarial anaemia (SMA) cases. ‘BOTH” refers to individuals who have both 
CM and SMA phenotypes. c) Overall sample counts and number of samples excluded by 
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each QC criterion. (*) denotes the number of samples removed after explicitly including 
samples with low heterozygosity in Gambia. (†) The Kenyan cohort included parents of a 
subset of case samples; these were not used in subsequent analyses. d) Plots of average 
genome-wide heterozygosity and missingness with outliers coloured, as output by the 
ABERRANT algorithm.
Extended Data Figure 2. 
Genotyped SNP quality control (QC) for the 3 discovery cohorts. a,b) Total numbers of pre- 
and post-QC SNPs on a) the autosomes and b) the X chromosome, and numbers of SNPs 
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excluded by each QC criteria. MAF refers to minor allele frequency, HWE to Hardy-
Weinberg equilibrium, Plate to the plate test of association and Diff. to the test of difference 
in frequency between males and females. Details of QC are given in Methods. c) Plot 
showing the –log10(P values) for the genotypic association test in the discovery data 
including the first 5 principal components as covariates. Grey dots show SNPs that are 
removed due to the QC as defined in Methods. The total fraction of SNPs removed from 
each cohort is given at the top of the plot.
Extended Data Figure 3. 
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Imputation performance. a,b) Empirical distribution of concordance and accuracy (r2) 
between typed and re-imputed SNPs in the three discovery cohorts. Solid lines represent 
SNPs with frequency below 5% and dashed lines represent SNPs with frequency of at least 
5%. c) Per-sample concordance and accuracy (type 0 r2) across the whole genome, as 
estimated by reimputing genotyped SNPs. Values are averaged over imputation chunks. d) 
Average accuracy between genotype and re-imputed SNPs in each cohort, plotted against 
frequency, in 1% frequency bins.
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Extended Data Figure 4. 
Top ten principal components (PCs) in a) Gambia, b) Malawi and c) Kenya. Where 
ethnicity was reported, points are coloured by ethnicity for ethnicities with at least 50 
samples. d) Logistic regression P-values and direction of effect for the top ten principal 
components on Severe Malaria status in each cohort. e) qq-plots for additive model 
association test P-values in Gambia, Malawi, Kenya, and for fixed-effect meta-analysis. 
Dashed lines represent the 99% confidence interval computed marginally at each variant. 
Circles and points represent points lying respectively outside and inside the 99% confidence 
interval. f) Comparison of association test P-values for logistic regression (SNPTEST, x-
axis) and linear mixed model (MMM, y-axis) for Gambia, Malawi, Kenya, and for fixed-
effect meta-analysis. Variants in tier 1 are coloured blue, with the lead marker at the 
FREM3/GYPE region coloured red.
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Extended Data Figure 5. 
Detail of Bayesian analysis of discovery cohorts. a) Visualisation of slices through the 
combined prior on effect sizes in three cohorts for mode-of-inheritance-specific models. Top 
row: slices through the prior effect size on Kenya (x-axis) and Malawi (y-axis) for constant 
effect size in Gambia (panels). Bottom row: slices through the prior effect size on Kenya (x-
axis) and Gambia (y-axis) for constant effect size in Malawi (panels). Red lines represent a 
factor of 10 in the prior density. b) Comparison of BFavg (x-axis) with the minimum fixed-
effect meta-analysis P-value minimized across additive, dominant, recessive or heterozygote 
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modes of inheritance (y-axis). Values are plotted on log10 and –log10 scales. Colour 
indicates the heterogeneity model of the model with the highest posterior weight. c) 
Sensitivity of BFavg to changes in prior. Plots show BFavg ratio (y-axis) plotted against one-
dimensional parameterisations of the prior (x-axis), for the 32 autosomal SNPs in tier 1. 
Solid lines represent variants with minor allele frequency < 5% averaged across populations, 
and dashed lines variants with minor allele frequency >= 5%. Black dots indicate the lead 
marker at the FREM3/GYPE locus. Colour indicates the effect size, mode of inheritance, or 
heterogeneity model for the model with highest posterior weight under the GWAS prior. 
Dashed grey vertical lines indicate the x-axis value corresponding to the prior used in the 
GWAS, and one-half and twice that value. Plots are parameterised by i) the prior standard 
deviation of the small-effect model keeping the prior standard deviation of the large and 
small-effect models in the ratio 0.75:0.2; ii-v) the prior weight on additive, dominant, 
recessive or heterozygote modes of inheritance; vi-x) the prior weight on fixed, correlated, 
independent, fixed-structured and correlated-structured models. For each parameterisation 
prior weights on other models are kept in the same relative proportion. For further details 
see Supplementary Note 4.
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Extended Data Figure 6. 
Strongest regions of association in the Bayesian analysis of the three discovery cohorts. Plot 
on left shows the log10 model- averaged Bayes Factor (BFavg). Table shows the SNP with 
the highest BFavg in each region (lead SNP), gene(s) of interest in the region, the model with 
the highest posterior weight at the lead SNP and its BF. Coloured points indicate the odds 
ratio (OR) and the protective allele frequency in Gambia (red), Malawi (green) and Kenya 
(Blue). The right hand columns indicate regions containing shared chimp-human haplotypes 
or coding SNPs4 (ABPs), blood group genes, or Immunoglobulin superfamily genes.
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Extended Data Figure 7. 
a) Evidence for association at directly-typed SNPs in the FREM3/GYPE, INPP4B and 
ARL14 regions. b) Posterior probability that variants in the FREM3/GYPE region are causal 
assuming a single variant in the region is causal50, based on the BFavg for typed and imputed 
variants. Dashed lines indicate the 95% and 99% credible sets. See Figure 1 legend for 
further details. c) Details of SNPs encoding the common MNS blood groups. Coordinates 
and alleles are with respect to the NCBI b37 human reference sequence. d) Evidence for 
possible independence of effects at the FREM3 and INPP4B loci in Kenya by conditional 
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analysis. Y-axis represents -log10(association P-value) conditional on the imputed dosage at 
rs184895969. Points are coloured by LD with the top SNP rs13103597. e) Forest plot 
showing sample size, estimated odds ratio and 95% confidence interval for the lead imputed 
SNP (rs149373719) in INPP4B under an additive model of association. f) Bar plot showing 
the posterior weight on different models of heterogeneity at rs149373719 under the prior 
used in the GWAS, assuming an additive model of association. g) Forest plot showing 
evidence in both discovery and replication samples in the Sequenom data at rs77389579 in 
INPP4B. See Figure 2 legend for further details.
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Extended Data Figure 8. 
Sequence homology, alignability and structural variation in the glycophorin region. a) co-
occurrence of 100-mers (upper triangle) and 25-mers (lower triangle) in the human reference 
sequence. Each point represents a kmer that maps to the locations indicated by the x and y 
axis positions, either on the same strand (black points) or opposite strands (red points). 
Green vertical lines in this and subsequent panels delineate the region of high homology 
surrounding the three glycophorins. b) the location of the lead GWAS marker, ABPs, and 
protein-coding genes in the region. c) alignability of the 100-mer at each position of the 
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reference, up to two mismatches. Values are taken from the UCSC genome browser 
mappability track and averaged over 5kb bins. d) IMPUTE info in Kenya for variants with 
frequency at least 5%, averaged over 5kb bins. e–f) coverage for samples from YRI and 
LWK in 1000G Phase 1 carrying esv2662558, carrying esv2668125, or not carrying either 
deletion, respectively. Coverage for each individual is normalised by the mean coverage for 
that individual across chromosome 1, and only computed at positions with alignability = 1 
for all 100-mers overlapping the position, and for reads with mapping quality at least 20. 
Values are averaged over 5kb (grey) and 10kb (blue) bins. Three samples with apparently 
erroneous calls in the 1000G Phase1 genotype release are coloured (NA18519, red; 
NA19185, yellow; NA19222, green) and assigned to the status indicated by their coverage 
profile. The bottom row represents a sample of 30 individuals not carrying the deletion 
selected at random in addition to the two with erroneous genotype calls. Coverage 
computation was performed using the BAM files available from the 1000G project in 
October 2014, downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data. Four African 
samples in the Phase 1 release were not assessed because they are not included in this 
directory.
Extended Data Figure 9. 
Correlation between the genotypes at SNPs of interest within the GYPE/A/B locus and 
reported gene transcription levels in samples from the YRI and LWK HapMap cohorts17. P 
values are for a trend test of association where more than one genotype class is present. Only 
assays targeting the glycophorins, and those with a P-value below 0.05 are shown.
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Extended Data Figure 10. 
Detail of enrichment analysis. a) Red histogram: the empirical distribution of the log10 
distance of observed tier 1 loci to the nearest ABP haplotype. Grey histogram: distribution 
of distances for 10,000 simulated tier 1 sets. b) The log10 distance of tier 1 (filled red 
circles) and tier 2 (empty circles) loci to the nearest ABP, plotted against their rank in BFavg 
order (stronger signals have lower rank). Loci are annotated with the nearest gene where a 
gene exists within the association region. Asterisks denote nearest genes that are also the 
nearest gene to an ABP shared haplotype. c) Empirical null distribution of the odds ratio for 
the enrichment of tier 1 loci in the set of genes closest to an ABP shared haplotype, based on 
Page 28
Nature. Author manuscript; available in PMC 2016 April 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
10,000 simulated SNP sets. The red asterisk and text indicate the odds ratio for the observed 
tier 1 loci. d) Distribution of the proportion of the genome which identifies a given gene as 
nearest, for genes in or not in the set annotated as nearest an ABP haplotype. Left: 
distribution of the length of the genome for which the given gene is unambiguously the 
closest gene. Middle: distribution of the number of SNPs in our study for which the given 
gene is the closest gene. Right: distribution of the number of SNPs in our study for which 
the given gene is the nearest gene within a recombination interval of 2.5cM±25kb around 
the SNP, as used to determine nearest genes to GWAS lead SNPs. e) Empirical P-values for 
enrichment of ABP haplotypes and coding SNPs in tier 1 and tier 2 GWAS regions. Second 
column: P-values for enrichment by gene overlap. Third to tenth column: P-values for 
enrichment by proximity at different length scales. †Results for simulations using SNPs 
frequency-matched to GWAS tier 1 loci in 1% frequency bins. ††Results for simulations 
excluding the regions of ABO, HBB, ATP2B4, FREM3, INPP4B, and HHIP-AS1.
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Figure 1. 
Signal of association with severe malaria across the FREM3/GYPE region. a) evidence for 
association (log10BFavg) in the discovery data. Black plusses denote SNPs that were directly 
typed, and black triangles denote SNPs selected for typing on the Sequenom platform. 
Dotted red vertical lines indicate a region of 0.25cM±25kb centred at the lead SNP 
(rs184895969). Coloured circles denote the correlation (outer circles) and |D’| (inner circles) 
with rs184895969 in controls, computed from imputed haplotypes. b) Polymorphisms 
shared between humans and chimpanzees, eQTLs, and previously reported associations with 
other phenotypes. c,d) Genes in the region and the HapMap combined recombination rate.
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Figure 2. 
Evidence for association at SNPs in the FREM3/GYPE region assuming an additive model 
of association. a) Forest plot showing sample size, estimated odds ratio and 95% confidence 
interval for the lead imputed SNP in each population and under fixed-effect meta-analysis. 
The frequency of the protective allele in controls in each population is shown to the right. b) 
The posterior weight on different models of heterogeneity at rs184895969 under the prior 
used in the GWAS. Model names are described in Methods. c) Forest plot for the 
Sequenom-typed SNP rs186873296 in discovery and replication samples, with fixed-effect 
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meta-analysis across all populations and across East African populations (here taken as 
Kenya, Malawi, Tanzania and Cameroon.)
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Figure 3. 
Haplotype analysis across the FREM3/GYPE region. Left hand panel shows haplotypes at 
7321 polymorphic SNPs between 144.5Mb and 145.2Mb on chromosome 4 in the LWK and 
YRI samples of the 1000 Genomes reference panel. Key variants (Methods and 
Supplementary Note 2) are enlarged for clarity and labelled, with reference and non-
reference alleles coloured blue and yellow respectively. On the right is the estimated 
topology of the genealogical tree at rs184895969. Dots indicate the position of the inferred 
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protective mutation in Kenya and the branch ancestral to the ABPs, and are labelled with the 
estimated odds ratios (OR).
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